NMC
NEA Management Company Portfolio holdings
AUM
$1.33B
This Quarter Return
+23.3%
1 Year Return
+85.82%
3 Year Return
+531.37%
5 Year Return
+304.32%
10 Year Return
+4,927.96%
AUM
$1.61B
AUM Growth
+$1.61B
(+7.4%)
Cap. Flow
-$42.6M
Cap. Flow
% of AUM
-2.64%
Top 10 Holdings %
Top 10 Hldgs %
70.44%
Holding
46
New
2
Increased
1
Reduced
7
Closed
2
Top Buys
| 1 |
Oric Pharmaceuticals
ORIC
|
$20.6M |
| 2 |
RGLS
Regulus Therapeutics
RGLS
|
$13M |
| 3 |
Xeris Biopharma Holdings
XERS
|
$926K |
Top Sells
| 1 |
Geron
GERN
|
$33M |
| 2 |
AFMD
Affimed
AFMD
|
$21.1M |
| 3 |
Sagimet Biosciences
SGMT
|
$10M |
| 4 |
MYND
Mynd.ai
MYND
|
$8.61M |
| 5 |
CBIO
Crescent Biopharma, Inc. Common Stock
CBIO
|
$2.79M |
Sector Composition
| 1 | Healthcare | 86.79% |
| 2 | Consumer Staples | 6.72% |
| 3 | Technology | 3.98% |
| 4 | Industrials | 2.07% |
| 5 | Communication Services | 0.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Arcellx
ACLX
$3.85B
| $260M | 16.17% | 3,745,262 | – | – |
|
2
CRISPR Therapeutics
CRSP
$4.71B
| $180M | 11.2% | 1,587,854 | – | – |
|
3
Rhythm Pharmaceuticals
RYTM
$6.85B
| $126M | 7.83% | 2,909,956 | – | – |
|
4
Savara
SVRA
$567M
| $122M | 7.56% | 24,471,264 | – | – |
|
5
Coursera
COUR
$1.88B
| $108M | 6.72% | 12,867,769 | – | – |
|
6
Korro Bio
KRRO
$217M
| $96.6M | 5.99% | 1,072,936 | – | – |
|
|
VRNA
7
Verona Pharma
VRNA
$9.16B
| $89.9M | 5.58% | 5,108,563 | – | – |
|
8
Monte Rosa Therapeutics
GLUE
$296M
| $54.2M | 3.37% | 7,692,298 | – | – |
|
9
NextNav
NN
$2.37B
| $53.9M | 3.34% | 8,189,156 | – | – |
|
10
CVRx
CVRX
$205M
| $43.2M | 2.68% | 2,370,542 | – | – |
|
|
11
Geron
GERN
$893M
| $42.2M | 2.62% | 12,776,409 -10,000,000 | -44% | -$33M |
|
12
Trevi Therapeutics
TRVI
$883M
| $39.2M | 2.44% | 11,370,376 | – | – |
|
13
Nkarta
NKTX
$151M
| $38.6M | 2.39% | 3,568,781 | – | – |
|
14
Celcuity
CELC
$2.17B
| $27M | 1.68% | 1,250,001 | – | – |
|
|
ADAP
15
Adaptimmune Therapeutics
ADAP
$15.6M
| $27M | 1.68% | 17,079,778 | – | – |
|
16
Black Diamond Therapeutics
BDTX
$157M
| $22.6M | 1.4% | 4,448,757 | – | – |
|
17
X4 Pharmaceuticals
XFOR
$84.2M
| $20.8M | 1.29% | 14,986,793 | – | – |
|
18
Phathom Pharmaceuticals
PHAT
$864M
| $20.8M | 1.29% | 1,960,169 | – | – |
|
|
19
Oric Pharmaceuticals
ORIC
$994M
| $20.6M | 1.28% | +1,500,000 | New | +$20.6M |
|
|
ZFOX
20
DELISTED
ZeroFox Holdings, Inc. Common Stock
ZFOX
| $20.2M | 1.26% | 18,068,513 | – | – |
|
21
Aurinia Pharmaceuticals
AUPH
$1.58B
| $19.9M | 1.23% | 3,969,834 | – | – |
|
22
Gossamer Bio
GOSS
$562M
| $18.7M | 1.16% | 15,838,009 | – | – |
|
|
INZY
23
DELISTED
Inozyme Pharma
INZY
| $18.7M | 1.16% | 2,437,689 | – | – |
|
|
RGLS
24
DELISTED
Regulus Therapeutics
RGLS
| $18.6M | 1.16% | 6,467,802 +4,522,223 | +232% | +$13M |
|
25
NeueHealth
NEUE
$59.2M
| $17.7M | 1.1% | 2,726,917 | – | – |
|